On November 6th, the second day of the China International Import Expo (CIIE), Wondfo, China’s POCT leader, reached cooperation with AstraZeneca, a global, science-led biopharmaceutical business, to promote the early screening and diagnosis of prostate cancer, and to facilitate the efficient clinical management of prostate cancer in Asia, Central America, Latin America, the Middle East, and parts of Africa.
 
Wondfo and AstraZeneca plan to screen 15,000 people for prostate cancer by the end of this year and complete the screening of over 300,000 people in cooperated countries worldwide in 2021.